BPC-157 & TB-500 Stack USA | Buy BPC-157 + TB-500 5mg | Research-Grade Peptides ≥99% Purity

The BPC-157 and TB-500 research stack combines two of the most extensively studied and mechanistically complementary repair-focused peptides in modern regenerative science — BPC-157, a synthetic 15-amino acid gastric-derived pentadecapeptide operating through simultaneous NO system, VEGFR2, and FAK-paxillin pathway activation, and TB-500, a synthetic 43-amino acid Thymosin Beta-4 peptide operating through G-actin sequestration and actin cytoskeletal regulation — studied together across wound healing, musculoskeletal repair, cardiovascular biology, neuroprotection, and broad tissue repair research for their complementary multi-pathway repair biology that engages fundamentally distinct but synergistically acting cellular repair mechanisms simultaneously — making this combination one of the most pharmacologically rational and actively researched dual-peptide repair stacks in modern pre-clinical regenerative science. Researchers and institutions across the USA can source verified, research-grade BPC-157 5mg + TB-500 5mg with fast domestic dispatch and full batch documentation included on both vials.

✅ ≥99% Purity — HPLC & Mass Spectrometry Verified

✅ Batch-Specific Certificate of Analysis (CoA) Included on Both Vials

✅ Sterile Lyophilised Powder | GMP Manufactured

✅ Fast Dispatch Across the USA | USA Peptides In Stock

What Is the BPC-157 + TB-500 Research Stack?

The BPC-157 + TB-500 research stack pairs two of the most biologically active, mechanistically well-characterised, and pre-clinically validated repair-promoting peptides available in modern regenerative science — combining their distinct and complementary mechanisms into a dual-peptide research system that engages tissue repair biology at multiple levels simultaneously.

BPC-157 — Body Protection Compound 157 — is a synthetic 15-amino acid pentadecapeptide derived from a protective protein found in human gastric juice. Its defining pharmacological feature is its simultaneous multi-pathway mechanism — engaging the nitric oxide (NO) system, VEGFR2-mediated angiogenic signalling, and FAK-paxillin cytoskeletal signalling concurrently — producing a broad cytoprotective and repair-promoting profile spanning gastrointestinal mucosal protection, tendon and ligament repair, muscle healing, bone regeneration, angiogenesis, neuroprotection, and wound healing. BPC-157’s gastric origin gives it exceptional stability in biological environments and makes GI mucosal protection its most classically characterised tissue research application — a unique capability not shared by any other repair peptide.

TB-500 — the synthetic form of Thymosin Beta-4 (Tβ4) — is a 43-amino acid peptide that is one of the most abundant intracellular peptides in virtually every nucleated mammalian cell. Its primary mechanism is high-affinity G-actin sequestration through the LKKTET motif — regulating actin polymerisation dynamics, cytoskeletal organisation, and the cell migration that underpins effective tissue repair across multiple cell types. TB-500 is additionally secreted extracellularly in response to injury — functioning as a tissue repair signalling molecule promoting endothelial cell migration, angiogenesis, and multi-tissue repair through cell surface and extracellular matrix interactions. Its most distinctive research strengths lie in cardiac repair and regeneration, corneal wound healing, and the fundamental actin cytoskeletal biology that drives cell motility across virtually all tissue repair contexts.

The scientific rationale for studying BPC-157 and TB-500 in combination is their mechanistic complementarity — they operate through fundamentally non-overlapping biological pathways that address different but synergistically important aspects of the tissue repair process. BPC-157 drives repair through NO-mediated cytoprotection, VEGFR2 angiogenic signalling, and FAK-paxillin cytoskeletal modulation. TB-500 drives repair through actin sequestration, G-actin/F-actin equilibrium regulation, and the actin dynamics-dependent cell migration that delivers repair cells to injury sites. Together they engage the repair process at the level of both vascular biology (through complementary angiogenic mechanisms), cytoskeletal dynamics (through both FAK-paxillin and actin sequestration pathways), and cytoprotective signalling (through NO system and Tβ4-mediated anti-inflammatory biology) — producing a multi-level repair research system more comprehensive than either peptide alone.

What Does the BPC-157 + TB-500 Stack Do in Research?

In controlled pre-clinical and laboratory settings, the BPC-157 + TB-500 combination has been studied across a wide range of regenerative, tissue biology, and pre-clinical repair research applications:

Complementary Angiogenesis Research Both BPC-157 and TB-500 promote angiogenesis through distinct mechanisms — BPC-157 through VEGFR2 signalling modulation and TB-500 through endothelial cell migration promotion via actin dynamics regulation. Studies examining both compounds in wound healing and tissue repair models have explored how these complementary pro-angiogenic mechanisms interact — examining whether dual pathway angiogenic stimulation produces additive vascular support for tissue repair compared to either compound alone.

Multi-Pathway Cytoskeletal Research BPC-157 modulates cytoskeletal signalling through the FAK-paxillin pathway — affecting cell adhesion complex dynamics and mechanosensing. TB-500 modulates cytoskeletal organisation through G-actin sequestration — directly regulating actin filament dynamics and polymerisation. Research examining both compounds explores how these complementary cytoskeletal mechanisms interact in cell migration and repair biology — providing a dual-pathway tool for studying the relationship between FAK-paxillin signalling and actin dynamics in tissue repair contexts.

Wound Healing Research Both BPC-157 and TB-500 are individually among the most active wound healing peptides in pre-clinical research — and combination studies have examined how their complementary mechanisms affect wound closure kinetics, granulation tissue quality, collagen deposition, and epithelial re-covering in skin and soft tissue injury models. Research has explored whether the combination engages more wound healing pathways simultaneously than either peptide alone.

Musculoskeletal Repair Research Both peptides have independently documented pre-clinical activity in musculoskeletal repair models — BPC-157 in tendon, ligament, and muscle repair, and TB-500 in muscle repair and actin cytoskeletal biology. Combination research has examined how their complementary repair mechanisms affect musculoskeletal healing parameters — exploring the interaction between NO system and VEGFR2-mediated repair signalling and actin dynamics-driven cell migration in muscle and connective tissue healing models.

Cardiovascular Research TB-500’s particularly strong cardiovascular repair profile — including its well-characterised cardioprotective and cardiac regeneration-promoting effects — combined with BPC-157’s multi-pathway cytoprotective activity has driven research examining the combination in pre-clinical cardiac biology models — exploring how actin-based cardiac progenitor cell migration and multi-pathway NO/VEGFR2 cytoprotection interact in models of cardiac ischaemia and repair.

Neuroprotection Research Both BPC-157 and TB-500 have independently documented neuroprotective effects in pre-clinical CNS models — and combination research has examined how their complementary neuroprotective mechanisms interact in brain and spinal cord injury models, exploring whether simultaneous multi-pathway neuroprotection produces enhanced neuronal survival and functional recovery parameters.

Anti-Inflammatory Research BPC-157 modulates the NO system with anti-inflammatory consequences, and TB-500 exerts anti-inflammatory effects through macrophage activity modulation and cytokine regulation. Studies examining the combination have explored how these complementary anti-inflammatory mechanisms interact in the inflammatory microenvironment of healing tissue — with the inflammatory phase of tissue repair considered a key area where dual-mechanism anti-inflammatory activity may engage multiple pathways simultaneously.

GI Biology Research BPC-157’s classically characterised GI mucosal protective activity — driven by NO system engagement and multi-pathway cytoprotection — represents a research area where TB-500’s actin-based cell migration promotion may complement GI epithelial repair biology. Combination research has examined how actin dynamics-driven GI epithelial cell migration interacts with BPC-157’s GI mucosal protective signalling in GI repair models.

Combination Repair Protocol Research The BPC-157 + TB-500 combination is used as a model dual-mechanism repair system in pre-clinical research examining the general question of whether mechanistically complementary repair peptide combinations produce additive or synergistic tissue repair outcomes compared to individual peptide administration — contributing to the broader research field of multi-peptide combination repair biology.

All applications are for research purposes only. BPC-157 and TB-500 as supplied are not intended for human therapeutic use.

What Do Studies Say About BPC-157 + TB-500?

The individual research profiles of BPC-157 and TB-500 are among the most extensive in pre-clinical regenerative science — and the combination is studied on the basis of their well-established mechanistic complementarity:

BPC-157 Research Profile: Decades of pre-clinical research have documented BPC-157’s cytoprotective and repair-promoting effects across GI, musculoskeletal, neurological, and vascular tissue models — with consistent documentation of NO system, VEGFR2, and FAK-paxillin pathway co-activation establishing it as the most mechanistically multi-pathway repair peptide in its class and one of the most reproducibly active repair compounds in pre-clinical research.

TB-500 Research Profile: An extensive body of pre-clinical research has characterised TB-500’s G-actin sequestration mechanism, cell migration promotion, cardiac repair activity, corneal wound healing biology, and neuroprotective effects — establishing it as the most fundamental and broadly expressed actin-sequestering repair peptide with a particularly distinctive cardiovascular research profile.

Mechanistic Complementarity: Research examining both compounds together has confirmed their mechanistic non-overlap — with BPC-157’s NO/VEGFR2/FAK-paxillin pathways and TB-500’s actin sequestration/cell migration biology representing distinct and non-redundant aspects of tissue repair biology that provide a strong scientific rationale for combination research protocols.

Combination Wound Healing: Pre-clinical studies examining the BPC-157 and TB-500 combination in wound healing models have explored the interaction between their complementary mechanisms — with research examining wound closure parameters, vascular support, and cellular repair biology when both peptides’ distinct pathways are simultaneously engaged.

Additive Repair Biology: Research interest in the BPC-157 + TB-500 combination is driven by the hypothesis that mechanistically non-overlapping repair pathways engaged simultaneously may produce more comprehensive tissue repair responses than single-mechanism approaches — a research question that has driven active pre-clinical investigation of this combination across multiple tissue repair contexts.

BPC-157 + TB-500 Stack vs Individual Compounds and Alternative Stacks

Feature	BPC-157 + TB-500 Stack	BPC-157 Alone	TB-500 Alone	GHK-Cu + BPC-157
Mechanisms Covered	NO system + VEGFR2 + FAK-paxillin + G-actin sequestration + actin dynamics	NO system + VEGFR2 + FAK-paxillin	G-actin sequestration + actin dynamics + cell migration	NO system + VEGFR2 + FAK-paxillin + copper/collagen/gene regulation
Tissue Repair Breadth	Broadest — multi-pathway vascular + cytoskeletal + cytoprotective	Broad multi-tissue but no actin sequestration biology	Broad but no GI protection or NO/VEGFR2 biology	Broad with added skin/collagen/ECM dimension
Cardiovascular Strength	Strong — TB-500 cardiac + BPC-157 cytoprotection	Moderate — NO/VEGFR2 cardiac cytoprotection	Very strong — cardiac regeneration / actin repair	Moderate — no dedicated cardiac regeneration component
GI Research Strength	Very strong — BPC-157 GI protection + TB-500 GI epithelial migration	Strongest GI protection of any single repair peptide	No dedicated GI protection activity	Very strong — BPC-157 GI + GHK-Cu mucosal biology
Actin Biology	Yes — TB-500 LKKTET G-actin sequestration	No actin sequestration biology	Primary mechanism	No actin sequestration biology
Best For	Broadest multi-mechanism repair / musculoskeletal / cardiac / wound healing combination research	GI-focused / multi-pathway repair / tendon / single-peptide research	Cardiac-focused / actin biology / corneal / single-peptide research	Skin-focused / collagen / ECM / wound healing combination research

Product Specifications

BPC-157 5mg

Parameter	Specification
Full Name	BPC-157 (Body Protection Compound 157)
Vial Size	5mg
Peptide Length	15 Amino Acids (Pentadecapeptide)
Sequence	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Primary Mechanisms	NO system / VEGFR2 / FAK-paxillin
Purity	≥99% (HPLC & MS Verified)
Form	Sterile Lyophilised Powder
Solubility	Sterile water, bacteriostatic water, PBS
Storage (Powder)	-20°C, protect from light
Storage (Reconstituted)	2–8°C, use within 28 days with bacteriostatic water
Manufacturing	GMP Manufactured

TB-500 5mg

Parameter	Specification
Full Name	TB-500 (Thymosin Beta-4 / Tβ4)
Vial Size	5mg
Peptide Length	43 Amino Acids
Primary Mechanism	G-actin sequestration via LKKTET motif
Key Actin-Binding Motif	LKKTET
Purity	≥99% (HPLC & MS Verified)
Form	Sterile Lyophilised Powder
Solubility	Sterile water, bacteriostatic water, PBS
Storage (Powder)	-20°C, protect from light
Storage (Reconstituted)	2–8°C, use within 28 days with bacteriostatic water
Manufacturing	GMP Manufactured

Buy BPC-157 + TB-500 5mg Stack in the USA — What’s Included

Every stack order includes full batch documentation for both vials:

✅ Batch-Specific Certificate of Analysis (CoA) — BPC-157 & TB-500

✅ HPLC Chromatogram — Both Vials

✅ Mass Spectrometry Confirmation — Both Vials

✅ Sterility & Endotoxin Testing Report — Both Vials

✅ Reconstitution Protocol — Both Peptides

✅ Technical Research Support

Frequently Asked Questions — BPC-157 + TB-500 Stack USA

Can I buy a BPC-157 + TB-500 research stack in the USA? Yes. We supply research-grade BPC-157 5mg and TB-500 5mg as a combined stack to researchers and institutions across the United States. Both vials include full batch documentation and are packaged to maintain peptide integrity during transit. Both compounds are supplied strictly for laboratory research use only.

Why are BPC-157 and TB-500 studied together in research? BPC-157 and TB-500 are studied together because their mechanisms are complementary rather than overlapping — they engage different but synergistically important aspects of tissue repair biology simultaneously. BPC-157 drives repair through NO-mediated cytoprotection, VEGFR2 angiogenic signalling, and FAK-paxillin cytoskeletal modulation. TB-500 drives repair through G-actin sequestration, actin dynamics regulation, and actin-dependent cell migration promotion. Together they address the repair process at the level of vascular biology, cytoskeletal dynamics, and cytoprotective signalling through entirely distinct molecular pathways — providing a more comprehensive multi-mechanism repair research system than either peptide alone can offer.

Are BPC-157 and TB-500 reconstituted together or separately in research? BPC-157 and TB-500 are reconstituted separately in research — each in its own vial with its own solvent volume appropriate to the desired working concentration. They are not combined in the same solution prior to reconstitution as lyophilised powders, and working solutions are typically prepared separately and administered independently in pre-clinical research protocols. Reconstituting peptides separately maintains accurate individual concentration control and avoids potential interactions between the two peptides in solution that could affect activity or stability measurements.

What purity is required for BPC-157 + TB-500 combination research? ≥98% is considered research-grade for both peptides, but ≥99% purity is strongly preferred for combination repair studies, wound healing experiments, musculoskeletal repair research, cardiovascular biology, and neuroprotection studies where compound purity of both peptides directly affects biological activity measurements and experimental reproducibility. All BPC-157 and TB-500 supplied for USA researchers are independently verified to ≥99%.

How are BPC-157 and TB-500 5mg each reconstituted for lab use? For both peptides — allow the vial to reach room temperature before opening. Add sterile water or bacteriostatic water slowly down the vial wall and swirl gently — do not shake. Both BPC-157 and TB-500 are well soluble in aqueous solvents and dissolve readily in standard research buffers. For multi-use protocols, bacteriostatic water extends reconstituted solution usability to 28 days at 2–8°C for both peptides. For longer storage of working solutions, aliquot into single-use volumes and store at -80°C. Avoid repeated freeze-thaw cycles for both peptides to maintain biological activity.

Research Disclaimer

BPC-157 and TB-500 are supplied exclusively for legitimate scientific research purposes conducted within licensed laboratory environments. These products are not intended for human consumption, self-administration, or any therapeutic application. They must be handled by qualified researchers in compliance with applicable US federal and state regulations and institutional ethics guidelines. By purchasing, you confirm that these compounds will be used solely for approved in-vitro or pre-clinical research purposes.